Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients.

Maeng CH, Lee HY, Kim YW, Choi MK, Hong JY, Jung HA, Lee KS, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Um SW, Ahn MJ.

Anticancer Res. 2013 Nov;33(11):5127-33.

PMID:
24222160
2.

Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.

Okuma Y, Hosomi Y, Nagamata M, Yamada Y, Sekihara K, Kato K, Hishima T, Okamura T.

Anticancer Res. 2013 Nov;33(11):5057-64.

PMID:
24222150
3.

Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.

Bar J, Damianovich M, Hout Siloni G, Dar E, Cohen Y, Perelman M, Ben Nun A, Simansky D, Yellin A, Urban D, Onn A.

Clin Lung Cancer. 2014 Mar;15(2):159-65. doi: 10.1016/j.cllc.2013.11.005. Epub 2013 Nov 14.

PMID:
24370118
4.

Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.

Uzunoglu FG, Kaufmann C, Wikman H, Güngör C, Bohn BA, Nentwich MF, Reeh M, Pantel K, Bockhorn M, Kutup A, Mann O, Izbicki JR, Vashist YK.

Ann Surg Oncol. 2012 Jul;19(7):2159-68. doi: 10.1245/s10434-012-2227-4. Epub 2012 Mar 7.

PMID:
22395975
5.
6.

Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.

Ko E, Lee BB, Kim Y, Lee EJ, Cho EY, Han J, Shim YM, Park J, Kim DH.

Clin Cancer Res. 2013 Mar 1;19(5):1204-12. doi: 10.1158/1078-0432.CCR-12-2848. Epub 2013 Jan 14.

7.

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.

J Thorac Oncol. 2012 Dec;7(12):1767-74. doi: 10.1097/JTO.0b013e3182745bcb.

8.
9.

High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer.

Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH, Zhang YK.

Med Oncol. 2012 Jun;29(2):618-26. doi: 10.1007/s12032-011-9923-y. Epub 2011 Apr 24.

PMID:
21516486
10.

Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer.

Shien K, Toyooka S, Kiura K, Matsuo K, Soh J, Yamane M, Oto T, Takemoto M, Date H, Miyoshi S.

Ann Surg Oncol. 2012 Aug;19(8):2685-92. doi: 10.1245/s10434-012-2302-x. Epub 2012 Mar 7.

11.

The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.

Kotsinas A, Evangelou K, Sideridou M, Kotzamanis G, Constantinides C, Zavras AI, Douglass CW, Papavassiliou AG, Gorgoulis VG.

Cancer Lett. 2008 Feb 8;259(2):177-85. Epub 2007 Nov 26.

PMID:
18037232
12.

Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.

Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G, Lin D, Wang L.

Clin Cancer Res. 2010 Apr 15;16(8):2383-90. doi: 10.1158/1078-0432.CCR-09-2793. Epub 2010 Mar 23.

13.

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F, Albus K, Serke M, Gerigk U, Schulte W, Töpelt K, Nogova L, Zander T, Engel-Riedel W, Stoelben E, Ko YD, Randerath W, Kaminsky B, Panse J, Becker C, Hellmich M, Merkelbach-Bruse S, Heukamp LC, Büttner R, Wolf J.

Oncotarget. 2015 Jan 20;6(2):1315-26.

14.

Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.

Ko E, Kim Y, Cho EY, Han J, Shim YM, Park J, Kim DH.

Ann Surg Oncol. 2013 Mar;20(3):1005-12. doi: 10.1245/s10434-012-2727-2. Epub 2012 Nov 1.

PMID:
23115005
15.

Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.

Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M.

Oncogene. 1998 May 14;16(19):2469-77.

16.

EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.

Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G.

Cancer Cytopathol. 2013 Oct;121(10):552-60. doi: 10.1002/cncy.21322. Epub 2013 Jun 18.

17.

Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.

Ikeda T, Nakamura Y, Yamaguchi H, Tomonaga N, Doi S, Nakatomi K, Iida T, Motoshima K, Mizoguchi K, Nagayasu T, Tsukamoto K, Kohno S.

Clin Lung Cancer. 2012 Sep;13(5):369-74. doi: 10.1016/j.cllc.2012.01.008. Epub 2012 Mar 10.

PMID:
22410386
18.

Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas.

Zhan P, Shen XK, Qian Q, Wang Q, Zhu JP, Zhang Y, Xie HY, Xu CH, Hao KK, Hu W, Xia N, Lu GJ, Yu LK.

Oncol Rep. 2012 Apr;27(4):1072-8. doi: 10.3892/or.2011.1605. Epub 2011 Dec 21.

19.

The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.

Massabeau C, Filleron T, Wakil G, Rouquette I, Bachaud JM, Leguellec S, Delisle MB, Toulas C, Mazieres J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2012 Jan;13(1):59-67. doi: 10.1016/j.cllc.2011.06.011.

PMID:
21856239
20.

The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.

Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, Dias-Santagata D, Mathisen D, Lanuti M.

Ann Thorac Surg. 2013 Sep;96(3):962-8. doi: 10.1016/j.athoracsur.2013.05.091. Epub 2013 Aug 8.

PMID:
23932319

Supplemental Content

Support Center